Genomic DNA of human hematopoietic stem and progenitor cells (HSPC gDNA)

The genomic DNA of human hematopoietic stem and progenitor cells (HSPCs) serves as the fundamental substrate for ex vivo gene therapy and genome editing interventions. HSPCs are multipotent cells capable of self-renewal and differentiation into all blood lineages, making their genome a critical target for correcting inherited hematological disorders such as sickle cell disease and beta-thalassemia. By modifying the gDNA within these cells—either through the insertion of functional genes using viral vectors or the precise editing of regulatory elements using CRISPR/Cas9—therapeutic changes are permanently encoded and passed down to all daughter blood cells. This approach allows for a one-time treatment that can provide long-term production of healthy red blood cells or immune cells. However, targeting the HSPC genome requires high precision to avoid off-target effects or insertional mutagenesis, which could lead to hematologic malignancies or clonal dominance.

Other names

Hematopoietic stem and progenitor cell genomeCD34+ cell genomic DNAHSPC DNA

Gene editing (e.g., CRISPR/Cas9-mediated double-strand breaks at specific loci like the BCL11A enhancer) or gene addition (e.g., lentiviral vector-mediated integration of functional globin genes) to modify the cellular phenotype and restore physiological function in progeny cells.